Original Publication Date: 29 March, 2014
Publication / Source: Biomarkers in Medicine
Authors: DaRue A Prieto, Donald J Johann Jr, Bih-Rong Wei, Xiaoying Ye, King C Chan, Dwight V Nissley, R Mark Simpson, Deborah E Citrin, Crystal L Mackall, W Marston Linehan & Josip Blonder
The discovery of clinically relevant cancer biomarkers using mass spectrometry (MS)-based proteomics has proven difficult, primarily because of the enormous dynamic range of blood-derived protein concentrations and the fact that the 22 most abundant blood-derived proteins constitute approximately 99% of the total plasma protein mass. Immunodepletion of clinical body fluid specimens (e.g., serum/plasma) for the removal of highly abundant proteins is a reasonable and reproducible solution. Often overlooked, clinical tissue specimens also contain a formidable amount of highly abundant blood-derived proteins present in tissue-embedded networks of blood/lymph capillaries and interstitial fluid.